Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Genomic Health, Inc. (GHDX) A Good Stock To Buy?

With market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, low commodity prices and economic turmoil in China, many smart money investors are keeping their optimism regarding the current bull run, while, still, hedging many of their long positions. However, as we know, big investors usually buy stocks with strong fundamentals, which is why we believe we can profit from imitating them. In this article, we are going to take a look at the smart money sentiment surrounding Genomic Health, Inc. (NASDAQ:GHDX).

Syda Productions

Syda Productions

Genomic Health, Inc. investors should pay attention to a decrease in hedge fund sentiment lately. GHDX was in 13 hedge funds’ portfolio at the end of the third quarter of 2015. There were 15 hedge funds in our database with GHDX holdings at the end of the previous quarter. At the end of this article we will also compare GHDX to other stocks including Oritani Financial Corp. (NASDAQ:ORIT), Wingstop Inc (NASDAQ:WING), and Manchester United PLC (NYSE:MANU) to get a better sense of its popularity.

Follow Genomic Health Inc (NASDAQ:GHDX)
Trade (NASDAQ:GHDX) Now!

To the average investor there are many signals shareholders use to grade stocks. A duo of the most under-the-radar signals are hedge fund and insider trading signals. Hedge fund experts at Insider Monkey have shown that, historically, those who follow the top picks of the top investment managers can beat the market by a solid amount (see the details here).

Now, we’re going to review the new hedge fund action encompassing Genomic Health, Inc. (NASDAQ:GHDX).

How have hedgies been trading Genomic Health, Inc. (NASDAQ:GHDX)?

At Q3’s end, a total of 13 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of -13% from the previous quarter. With hedgies’ sentiment swirling, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their holdings substantially.

Healthcare hedge fund Baker Bros. Advisors, managed by Julian Baker and Felix Baker, holds the most valuable position in Genomic Health, Inc. (NASDAQ:GHDX). Baker Bros. Advisors has a $289 million position in the stock, comprising 2.7% of its 13F portfolio. The second most bullish hedge fund manager is Camber Capital Management, led by Stephen DuBois, holding a $51.8 million position; 4.4% of its 13F portfolio is allocated to the company. Remaining hedgies that hold long positions include James E. Flynn’s Deerfield Management, Israel Englander’s Millennium Management and Millennium Management Subsidiary’s Decade Capital Management.

Because Genomic Health, Inc. (NASDAQ:GHDX) has faced declining sentiment from the smart money, it’s easy to see that there is a sect of money managers who sold off their entire stakes heading into Q4. At the top of the heap, Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital dumped the largest stake of the “upper crust” of funds followed by Insider Monkey, totaling an estimated $1 million in stock. Vishal Saluja and Pham Quang’s fund, Endurant Capital Management, also sold off its stock, about $0.8 million worth. These transactions are intriguing to say the least, as aggregate hedge fund interest dropped by 2 funds heading into Q4.

Let’s go over hedge fund activity in other stocks similar to Genomic Health, Inc. (NASDAQ:GHDX). We will take a look at Oritani Financial Corp. (NASDAQ:ORIT), Wingstop Inc (NASDAQ:WING), Manchester United PLC (NYSE:MANU), and JinkoSolar Holding Co., Ltd. (NYSE:JKS). All of these stocks’ market caps resemble GHDX’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
ORIT 12 40620 -1
WING 10 21395 -4
MANU 9 92626 -1
JKS 6 46179 -6

As you can see these stocks had an average of 9.25 hedge funds with bullish positions and the average amount invested in these stocks was $50 million. Oritani Financial Corp. (NASDAQ:ORIT) is the most popular stock in this table. On the other hand JinkoSolar Holding Co., Ltd. (NYSE:JKS) is the least popular one with only 6 bullish hedge fund positions. Compared to these stocks Genomic Health, Inc. (NASDAQ:GHDX) is more popular among hedge funds. More importantly, hedge funds actually increased the total amount they invested in this company. Camber Capital increased its stake by 17% to $52 million. So it may even be safe to say that Arrowstreet and  Endurant Capital were selling to Camber. Overall, hedge funds owned more than 58% of this stock’s outstanding shares. Considering that hedge funds are fond of this stock, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!